Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
OGN Stock Forecast 2026-2027
$13.36
Current Price
$3.51B
Market Cap
Buy 0
Hold 4
Sell 1
Wall St Analyst Ratings
Distance to OGN Price Targets
+4.8%
To High Target of $14.00
-13.9%
To Median Target of $11.50
-40.1%
To Low Target of $8.00
OGN Price Momentum
+0.1%
1 Week Change
+0.3%
1 Month Change
+39.7%
1 Year Change
+86.3%
Year-to-Date Change
-0.9%
From 52W High of $13.48
+134.8%
From 52W Low of $5.69
📊 TOP ANALYST CALLS
Did OGN Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Organon is one of their latest high-conviction picks.
Latest OGN Stock Price Targets & Analyst Predictions
Based on our analysis of 3 Wall Street analysts, OGN has a neutral consensus with a median price target of $11.50 (ranging from $8.00 to $14.00). The overall analyst rating is Hold (5.6/10). Currently trading at $13.36, the median forecast implies a -13.9% downside. This outlook is supported by 0 Buy, 4 Hold, and 1 Sell ratings.
The most optimistic forecast comes from Navann Ty at BNP Paribas, projecting a 4.8% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
OGN Analyst Ratings
0
Buy
4
Hold
1
Sell
OGN Price Target Range
Low
$8.00
Average
$11.50
High
$14.00
Current: $13.36
Latest OGN Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for OGN.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 29, 2026 | BNP Paribas | Navann Ty | Neutral | Downgrade | $14.00 |
| Apr 28, 2026 | Piper Sandler | David Amsellem | Neutral | Upgrade | $14.00 |
| Feb 24, 2026 | Barclays | Underweight | Maintains | $N/A | |
| Dec 9, 2025 | Barclays | Underweight | Initiates | $N/A | |
| Nov 11, 2025 | JP Morgan | Underweight | Maintains | $N/A | |
| Nov 11, 2025 | Morgan Stanley | Equal-Weight | Maintains | $N/A | |
| May 15, 2025 | Piper Sandler | Overweight | Maintains | $N/A | |
| May 5, 2025 | Morgan Stanley | Equal-Weight | Maintains | $N/A | |
| Apr 9, 2025 | Morgan Stanley | Equal-Weight | Maintains | $N/A | |
| Feb 14, 2025 | Barclays | Overweight | Maintains | $N/A | |
| Feb 14, 2025 | Morgan Stanley | Equal-Weight | Maintains | $N/A | |
| Sep 6, 2024 | JP Morgan | Underweight | Downgrade | $N/A | |
| May 6, 2024 | Goldman Sachs | Neutral | Maintains | $N/A | |
| May 3, 2024 | Goldman Sachs | Neutral | Maintains | $N/A | |
| Apr 29, 2024 | Piper Sandler | Overweight | Maintains | $N/A | |
| Feb 20, 2024 | Goldman Sachs | Neutral | Maintains | $N/A | |
| Nov 22, 2023 | Piper Sandler | Overweight | Maintains | $N/A | |
| Nov 3, 2023 | Goldman Sachs | Neutral | Downgrade | $N/A | |
| Oct 25, 2023 | Piper Sandler | Overweight | Maintains | $N/A | |
| Oct 11, 2023 | Morgan Stanley | Equal-Weight | Maintains | $N/A |
Organon & Co. (OGN) Competitors
The following stocks are similar to Organon based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Organon & Co. (OGN) Financial Data
Organon & Co. has a market capitalization of $3.51B with a P/E ratio of 14.4x. The company generates $6.16B in trailing twelve-month revenue with a 4.0% profit margin.
Revenue growth is -3.5% quarter-over-quarter, while maintaining an operating margin of +18.7% and return on equity of +34.0%.
Valuation Metrics
Market Cap
$3.51B
Enterprise Value
$10.96B
P/E Ratio
14.4x
PEG Ratio
0.2x
Price/Sales
0.6x
Growth & Margins
Revenue Growth (YoY)
-3.5%
Gross Margin
+53.6%
Operating Margin
+18.7%
Net Margin
+4.0%
EPS Growth
+67.8%
Financial Health
Cash/Price Ratio
+31.8%
Current Ratio
2.0x
Debt/Equity
948.9x
ROE
+34.0%
ROA
+5.9%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Organon & Co. (OGN) Business Model
About Organon & Co.
What They Do
Develops innovative health solutions and therapies.
Business Model
The company generates revenue by developing and selling a diverse portfolio of prescription therapies, primarily focusing on women’s health, biosimilars, and established brands. Their offerings include contraceptives, menopause treatments, fertility solutions, and oncology biosimilars, which cater to significant therapeutic needs globally.
Additional Information
Founded in 2020 and headquartered in Jersey City, New Jersey, the company has a strong presence in Europe, Canada, the United States, Asia Pacific, and Japan. Organon & Co. emphasizes research and development to advance therapies in women’s health and biosimilars while maintaining a reliable lineup of established products.
Company Information
Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
10,000
CEO
Mr. Kevin Ali
Country
United States
IPO Year
2021
Website
www.organon.comOrganon & Co. (OGN) Latest News & Analysis
Latest News
Quick Summary
Brodsky & Smith is investigating Organon & Co.'s Board for potential fiduciary duty breaches related to its $14.00 per share sale to Sun Pharmaceutical, valuing the deal at $11.75 billion.
Why It Matters
The investigation into Organon's Board raises concerns about potential fiduciary breaches, which could impact shareholder value and the stock's future performance.
Source: Newsfile Corp
Market Sentiment:
Neutral
Quick Summary
Organon (OGN) has gained significant attention from Zacks.com users, indicating potential interest in the stock's future performance and prospects.
Why It Matters
Increased interest in Organon (OGN) may indicate potential volatility or growth, prompting investors to assess its fundamentals and market position for strategic decisions.
Source: Zacks Investment Research
Market Sentiment:
Positive
Hanmi Pharmaceutical Partners with Organon to Export Combination Therapies to Southeast Asia
17 days ago
Quick Summary
Hanmi Pharmaceutical signed a supply agreement with Organon to export three combination therapies to Malaysia and the Philippines, expanding their partnership in Southeast Asia.
Why It Matters
Hanmi Pharmaceutical's supply agreement with Organon for combination therapies signals growth potential in Southeast Asia, likely boosting revenue and market presence, which can positively impact stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Organon (OGN) is currently a focus for Zacks.com users, indicating growing interest. Investors may want to monitor developments related to the stock.
Why It Matters
Increased attention on Organon (OGN) suggests potential volatility and trading opportunities, impacting investor sentiment and stock performance.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Organon will present 8 abstracts on women's health, biosimilars, and general medicines at ISPOR 2026, focusing on affordability, access, and adoption issues.
Why It Matters
Organon's presentation on women's health and biosimilars may signal potential growth areas, influencing investor sentiment and stock performance based on market demand and innovation.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Organon (OGN) is currently drawing significant attention from Zacks.com users, indicating investor interest that could influence its stock performance.
Why It Matters
Increased interest in Organon (OGN) suggests potential volatility or opportunity, highlighting factors that could impact stock performance and investment strategies.
Source: Zacks Investment Research
Market Sentiment:
Positive
Frequently Asked Questions About OGN Stock
What is Organon & Co.'s (OGN) stock forecast for 2026?
Based on our analysis of 3 Wall Street analysts, Organon & Co. (OGN) has a median price target of $11.50. The highest price target is $14.00 and the lowest is $8.00.
Is OGN stock a good investment in 2026?
According to current analyst ratings, OGN has 0 Buy ratings, 4 Hold ratings, and 1 Sell ratings. The stock is currently trading at $13.36. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for OGN stock?
Wall Street analysts predict OGN stock could reach $11.50 in the next 12 months. This represents a -13.9% decrease from the current price of $13.36. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Organon & Co.'s business model?
The company generates revenue by developing and selling a diverse portfolio of prescription therapies, primarily focusing on women’s health, biosimilars, and established brands. Their offerings include contraceptives, menopause treatments, fertility solutions, and oncology biosimilars, which cater to significant therapeutic needs globally.
What is the highest forecasted price for OGN Organon & Co.?
The highest price target for OGN is $14.00 from Navann Ty at BNP Paribas, which represents a 4.8% increase from the current price of $13.36.
What is the lowest forecasted price for OGN Organon & Co.?
The lowest price target for OGN is $8.00 from at , which represents a -40.1% decrease from the current price of $13.36.
What is the overall OGN consensus from analysts for Organon & Co.?
The overall analyst consensus for OGN is neutral. Out of 3 Wall Street analysts, 0 rate it as Buy, 4 as Hold, and 1 as Sell, with a median price target of $11.50.
How accurate are OGN stock price projections?
Stock price projections, including those for Organon & Co., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 7, 2026 5:16 PM UTC